The safety and efficacy of DiKineTM products have been clinically validated by two of Evive’s products:
- F-627, a recombinant human G-CSF-Fc dimer, once per chemotherapy cycle injection is as efficacious and safe as G-CSF, which requires 5 injections per chemotherapy cycle.
- F-652, recombinant human IL-22-Fc dimer, has also been shown to be safe and efficacious as weekly injections in treating acute graft-versus-host disease (aGvHD). The U.S. FDA granted F-652 orphan drug status for the treatment of aGvHD in October 2019.
- F-652 has also been shown to be safe and efficacious as weekly injections in treatment of acute alcoholic hepatitis (AH).
- F-899, recombinant long-acting growth hormone with targeting dosing frequency of 10-14 days.
Another advantage of the DiKineTM platform is that it leverages a proven safety profile from the mammalian cell-based (CHO) expression system. Compared to bacteria-expressed cytokine or hormone therapies, the eukaryotic system provides folding and modifications of DiKineTM assets closer to their endogenous counterparts, optimizing safety, particularly in minimizing immunogenicity concerns.
Long-acting Multi-specific Antibodies Platform
Evive’s long-acting multi-specific platform, serves as the basis of many of the products in Evive’s pre-clinical product pipeline. The platform builds upon ItabTM, a partner platform that has historically yielded two products that have successfully entered human clinical trials. The platform provides significant flexibility to adapt to mono-targeting and multi-targeting agonists or antagonists, and is being used to quickly evaluate and develop new drug molecules.